About Nabriva
Nabriva is a publicly listed company based in Vienna (Austria) founded in 2006. Pleuromutilin antibiotics are developed for MDR infections. Nabriva has raised $193.08 million across 5 funding rounds from investors including Novartis, Hercules Capital and Orbimed. Nabriva has completed 1 acquisition, including Zavante. Nabriva offers products and services including XENLETA, CONTEPO, and SIVEXTRO. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is NABRIVA THERAPEUTICS PLC.
Company details
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABPVABP, and prosthetic joined infections (phase I). The antibiotic binds to a specific site on the bacterial ribosome responsible for bacterial protein synthesis. It has also developed Contepo (IV) for treating cUTI (NDAMAA filing) and pediatric indications (phase I).
- Headquarters Vienna, Austria
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nabriva.com
- Social LinkedIn X
- Legal Name Nabriva Therapeutics Plc
- Annual Revenue$36.94 M (USD)27.82as on Dec 31, 2022
- Net Profit-$57.19 M (USD)-15.64as on Dec 31, 2022
- EBITDA-$55.27 M (USD)-14.74as on Dec 31, 2022
- Total Equity Funding$193.08M (USD)
in 5 rounds
- Latest Funding Round$25M (USD), Debt – Conventional
Dec 2018
- InvestorsNovartis
& 9 more
- Investments & Acquisitions
Products & Services of Nabriva
Nabriva offers a comprehensive portfolio of products and services, including XENLETA, CONTEPO, and SIVEXTRO.
Treats serious bacterial infections in patients.
Addresses urinary tract and other infections.
Promoted for skin and soft tissue infections.
Funding Insights of Nabriva
Nabriva has successfully raised a total of $193.08M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $193.08M
- Total Rounds 5
- Last Round Debt – Conventional — $25M
- First Round $50.79M
(Jan 2006)
- Investors Count 10
All 5 funding rounds of Nabriva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $25M | Debt – Conventional | – | – | |
| Jul 2018 | $21.3M | Post-IPO | – | – | – |
| Apr 2015 | $120M | Series B | – | – | |
| Oct 2009 | $22.29M | Private Equity Round | – | – | |
| Jan 2006 | $50.79M | Private Equity Round | – | – |
10 investors in total: 10 institutional.
Investors in Nabriva
Nabriva has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Hercules Capital and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Venture capital investments are made in innovative healthcare companies. | phase4-partners.com | London, United Kingdom | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Early & late stage life sciences focused VC firm funding companies in the US and Europe | global-life-science-ventures.com | Munich, Germany | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
| ecor1cap.com | ||||
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Nabriva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nabriva
12 people are tracked at Nabriva (4 in leadership, 5 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Steven Gelone | President & COO | Leadership |
Bruno Fontanot, CPA, MBA | Senior Director, Financial Reporting & Compliance, Treasurer - U.S. | Leadership |
Paukner Susanne | Vice President, Microbiology | Leadership |
Christine Guico-Pabia | Chief Medical Officer | Leadership |
Daniel Burgess | Chairman | Board & advisors |
Carrie Bourdow | Director | Board & advisors |
Stephen Webster | Director | Board & advisors |
Colin Broom | Director | Board & advisors |
Mark Corrigan | Director | Board & advisors |
Peter Micuch | Senior Research Officer | Team |
Boyd Waverley | Territory Business Manager | Team |
Christopher Naftzger | General Counsel | Team |
Complete people profiles for Nabriva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Nabriva
Nabriva is a publicly listed company on the OTC with ticker symbol NBRVF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jun 2017
- Listed onNASDAQ: NBRV
- Listed entityNabriva Therapeutics plc
- Exchange sectorHealth technology
- ISINIE000OZRGNV6
- Share price$0.00 · 2026-05-11
- Market capitalisation$3.23
- Volume (last session)520
- Analyst consensusNo rating
Financials of Nabriva
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $36.9M | -$57.2M | -$55.3M |
| 2021 | $28.9M | -$49.5M | -$48.2M |
| 2020 | $5.0M | -$69.5M | -$65.3M |
Detailed financial statements for Nabriva
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nabriva
Nabriva has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zavante.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections. | zavante.com | San Diego, United States | 2015 | Jul 2018 | •••• |
Complete acquisition details for Nabriva
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Nabriva
5 dated milestones of Nabriva across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Nabriva is founded.
- Funding First funding round of $50.8M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Zavante.
- Funding Latest funding round, Debt – Conventional, of $25.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nabriva
Complete news archive for Nabriva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nabriva
Nabriva was founded in 2006.
Nabriva is headquartered in Vienna, Austria.
Nabriva is a funded company, having raised a total of $193.08M across 5 funding rounds to date. The company's 1st funding round was a Private Equity Round of $50.79M, raised on Jan 2006.
Annual revenue of Nabriva is $36.94M as on Dec 31, 2022.
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABPVABP, and prosthetic joined infections (phase I). The antibiotic binds to a specific site on the bacterial ribosome responsible for bacterial protein synthesis. It has also developed Contepo (IV) for treating cUTI (NDAMAA filing) and pediatric indications (phase I).
Nabriva offers XENLETA, CONTEPO, and SIVEXTRO.
Yes, Nabriva is publicly traded on OTC under the ticker symbol NBRVF.
Nabriva has made 1 acquisition, including Zavante.
Nabriva has 10 investors. Key investors include Novartis, Hercules Capital, Orbimed, HBM Healthcare Investments, and EcoR1.
Nabriva operates through Nabriva Therapeutics Plc.